Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-γ and tumor necrosis factor-α priming

Cancer Research

Volumn 70, Issue 20, 2010, Pages 7742-7747

  Romieu Mourez, Raphaëlle ^a   François, Moïra ^a   Abate, Amanda ^a   Boivin, Marie Noëlle ^a   Birman, Elena ^a   Bailey, Dana ^b   Bramson, Jonathan L ^b   Forner, Kathy ^a   Young, Yoon Kow ^a   Medin, Jeffrey A ^c   Galipeau, Jacques ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BREAST TUMOR; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE COUNT; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STROMA CELL; TUMOR IMMUNITY;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CLONING, MOLECULAR; FEMALE; HUMANS; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RATS; RECEPTOR, ERBB-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049297908     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0296     Document Type: Article

References (20)

1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36.
2. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21. (Pubitemid 38745993)
3. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-63. (Pubitemid 47063057)
4. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-34. (Pubitemid 46053063)
5. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009;27:1954-62.
6. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-γ- stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006;107:2570-7. (Pubitemid 43348704)
7. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 2006;107:4817-24.
8. Romieu-Mourez R, Francois M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-γ, TGF-β, and cell density. J Immunol 2007;179:1549-58.
9. Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. StemCells 2008;26:1275-87.
10. Francois M, Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009;114:2632-8.
11. Mossoba ME, Walia JS, Rasaiah VI, et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 2008;16:607-17.
12. Ng P, Parks RJ, Cummings DT, Evelegh CM, Graham FL. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther 2000;11:693-9. (Pubitemid 30180274)
13. Bramson JL, Hitt M,AddisonCL,MullerWJ,Gauldie J,GrahamFL.Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin 12. Hum Gene Ther 1996;7:1995-2002.
14. Rovero S, Amici A, Di CE, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
15. Boggio K, Nicoletti G, Di CE, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96. (Pubitemid 28369147)
16. Whittington PJ, Piechocki MP, Heng HH, et al. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res 2008;68:7502-11.
17. Lutz MB, Kukutsch N, Ogilvie ALJ, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-99.
18. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007;67:1326-34.
19. Cipriani B, Fridman A, Bendtsen C, et al. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 2008;19:670-80. (Pubitemid 352009912)
20. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994;13:3302-11. (Pubitemid 24226945)